Please assess the completion status of the following clinical trial:

Trial Title: Will Hydroxychloroquine Impede or Prevent COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant is willing and able to provide informed consent.~2. Participant is 18-75 years of age.~3. Participant does not have symptoms of respiratory infection, including cough, fevers (temperature \>38.0C), difficulty breathing, shortness of breath, chest pains, malaise, myalgia, headaches, nausea or vomiting, or other symptoms associated with COVID-19.~4. Participant is willing to provide blood samples for the study.~5. Subject agrees to all aspects of the study.~6. The participant has no known allergies or contraindications (as stated in the consent form) to the use of hydroxychloroquine (HCQ) as noted in the exclusion criteria and Pharmacy sections.~Exclusion Criteria:~1. Does not meet inclusion criteria.~2. Participant unable or unwilling to provide informed consent.~3. Participant has any of the symptoms above or screens positive for possible COVID-19 disease.~4. Participant is currently enrolled in a study to evaluate an investigational drug.~5. Vulnerable populations deemed inappropriate for study by the site Principal Investigator.~6. The participant has a known allergy/hypersensitivity or has a medication or co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or renal failure) that prevents the use of HCQ (see pharmacy section).~7. The participant is a woman of childbearing age whose pregnancy status is unknown and is not willing to use 2 methods of contraception.~8. The participant is pregnant or nursing.~9. The participant was diagnosed with retinopathy prior to study entry.~10. The participant has a diagnosis of porphyria prior to study entry.~11. The participant has renal failure with a creatinine clearance of \<10 ml/min, pre-dialysis or requiring dialysis.~12. The Participant has a family history of Sudden Cardiac Death.~13. The participant is currently on diuretic therapy.~14. The participant has a history of known Prolonged QT Syndrome.~15. The participant is already taking any of the following medications: Abiraterone acetate, Agalsidase, Amodiaquine, Azithromycin, Conivaptan, Dabrafenib, Dacomitinib, Dapsone (Systemic), Digoxin, Enzalutamide, Fusidic Acid (Systemic), Idelalisib, Lanthanum, Lumefantrine, Mefloquine, Mifepristone, Mitotane, Pimozide, QT-prolonging Agents, Stiripentol).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Study Drug - Daily Dose (Type: ACTIVE_COMPARATOR): The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
- Study Drug - Weekly Dose (Type: ACTIVE_COMPARATOR): The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria.
- Placebo (Type: ACTIVE_COMPARATOR): All treatment groups will receive placebo pills to have the patients take 2 pills a day. The randomized placebo arm will receive placebo pills made to resemble the daily dosing of HCQ. Similarly, the once a week treatment arm will receive placebo pills for the days not on HCQ medication.
- Non-Randomized Active Comparator (Type: ACTIVE_COMPARATOR): A non-randomized comparator group will be enrolled in the study comprising of healthcare workers and first responders who are chronically on oral hydroxychloroquine as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.

Based on this trial design, predict the completion outcome and termination type (if applicable).